HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

Optimal Duration of DAPT with Oral Anticoagulation After PCI?: 1 Month vs. 3 Months

While the benefits of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor are recognized, its...
solaci -
Learn More
Other

AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

Given the obesity pandemic projected for the year 2035, it is imperative to address this disease as...
solaci -
Learn More
Antiplatelet

AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Subclinical atrial fibrillation (AF), generally asymptomatic and of short duration, often requires continuous long-term monitoring using pacemakers...
solaci -
Learn More
Antithrombotic Anticoagulants

Acute Pulmonary Thromboembolism: When Anticoagulation Alone May Not Be Enough

In recent times, pulmonary thromboembolism (PTE) has been the subject of growing research due to its persistent...
solaci -
Learn More
Antiplatelet

TCT 2023 | COMPARE 60/80 HBR TRIAL

This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet...
solaci -
Learn More
Acute coronary syndromes

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to:...
solaci -
Learn More
Antiplatelet

Anti-Lipid Therapy in PCI Patients: Monotherapy with Statins or Combination?

According to several studies, in patients with high-risk atherosclerotic disease, such as those affected by coronary artery...
solaci -
Learn More
Acute coronary syndromes

Substudy TALOS AMI: from Ticagrelor to Clopidogrel in Patients with High Risk of Bleeding and AMI

The preference for the use of potent P2Y12 inhibitors such as ticagrelor and prasugrel in patients with...
solaci -
Learn More